Abstract

Background: The National Lung Screening Trial demonstrated that screening for lung cancer improved overall survival (OS) and reduced lung cancer mortality in the 55- to 74-year-old age group by increasing the proportion of cancers detected at an early stage. Because of the increasing life expectancy of the American population, we investigated whether screening for lung cancer might benefit men and women aged 75-84 years. Materials/Methods: Rates of non-small cell lung cancer (NSCLC) from 2000 to 2009 were calculated in both younger and older age groups using the surveillance epidemiology and end reporting database. OS and lung cancer-specific survival (LCSS) in patients with Stage I NSCLC diagnosed from 2004 to 2009 were analyzed to determine the effects of age and treatment. Results: The per capita incidence of NSCLC decreased in the 55-74 cohort, but increased in the 75-84 cohort over the study period. Crude lung cancer death rates in the two age groups who had no specific treatment were 39.5 and 44.9%, respectively. These rates fell in both age groups when increasingly aggressive treatment was used. Rates of OS and LCSS improved significantly with increasingly aggressive treatment in the 75-84 age group. The survival benefits of increasingly aggressive treatment in 75- to 84-year-old females did not differ from their counterparts in the younger cohort. Conclusion: Screening for lung cancer might be of benefit to individuals at increased risk of lung cancer in the 75-84 age group. The survival benefits of aggressive therapy are similar in females between 55-74 and 75-84 years old.

Original languageEnglish (US)
Article numberArticle 37
JournalFrontiers in Oncology
Volume4 MAR
DOIs
StatePublished - Jan 1 2014

Fingerprint

Lung Neoplasms
Age Groups
Survival
Non-Small Cell Lung Carcinoma
Therapeutics
Mortality
Life Expectancy
Epidemiology
Cohort Studies
Survival Rate
Databases
Lung
Incidence
Population
Neoplasms

All Science Journal Classification (ASJC) codes

  • Oncology
  • Cancer Research

Cite this

Varlotto, J. M., DeCamp, M. M., Flickinger, J. C., Lake, J., Recht, A., Belani, C. P., ... Yao, N. (2014). Would screening for lung cancer benefit 75- to 84-year-old residents of the United States? Frontiers in Oncology, 4 MAR, [Article 37]. https://doi.org/10.3389/fonc.2014.00037
Varlotto, John M. ; DeCamp, Malcolm M. ; Flickinger, John C. ; Lake, Jessica ; Recht, Abram ; Belani, Chandra P. ; Reed, Michael F. ; Toth, Jennifer W. ; Mackley, Heath B. ; Sciamanna, Christopher N. ; Lipton, Alan ; Ali, Suhail M. ; Mahraj, Richkesvar P.M. ; Gilbert, Christopher R. ; Yao, Nengliang. / Would screening for lung cancer benefit 75- to 84-year-old residents of the United States?. In: Frontiers in Oncology. 2014 ; Vol. 4 MAR.
@article{2962fbc391c44852ac73040f1fab319d,
title = "Would screening for lung cancer benefit 75- to 84-year-old residents of the United States?",
abstract = "Background: The National Lung Screening Trial demonstrated that screening for lung cancer improved overall survival (OS) and reduced lung cancer mortality in the 55- to 74-year-old age group by increasing the proportion of cancers detected at an early stage. Because of the increasing life expectancy of the American population, we investigated whether screening for lung cancer might benefit men and women aged 75-84 years. Materials/Methods: Rates of non-small cell lung cancer (NSCLC) from 2000 to 2009 were calculated in both younger and older age groups using the surveillance epidemiology and end reporting database. OS and lung cancer-specific survival (LCSS) in patients with Stage I NSCLC diagnosed from 2004 to 2009 were analyzed to determine the effects of age and treatment. Results: The per capita incidence of NSCLC decreased in the 55-74 cohort, but increased in the 75-84 cohort over the study period. Crude lung cancer death rates in the two age groups who had no specific treatment were 39.5 and 44.9{\%}, respectively. These rates fell in both age groups when increasingly aggressive treatment was used. Rates of OS and LCSS improved significantly with increasingly aggressive treatment in the 75-84 age group. The survival benefits of increasingly aggressive treatment in 75- to 84-year-old females did not differ from their counterparts in the younger cohort. Conclusion: Screening for lung cancer might be of benefit to individuals at increased risk of lung cancer in the 75-84 age group. The survival benefits of aggressive therapy are similar in females between 55-74 and 75-84 years old.",
author = "Varlotto, {John M.} and DeCamp, {Malcolm M.} and Flickinger, {John C.} and Jessica Lake and Abram Recht and Belani, {Chandra P.} and Reed, {Michael F.} and Toth, {Jennifer W.} and Mackley, {Heath B.} and Sciamanna, {Christopher N.} and Alan Lipton and Ali, {Suhail M.} and Mahraj, {Richkesvar P.M.} and Gilbert, {Christopher R.} and Nengliang Yao",
year = "2014",
month = "1",
day = "1",
doi = "10.3389/fonc.2014.00037",
language = "English (US)",
volume = "4 MAR",
journal = "Frontiers in Oncology",
issn = "2234-943X",
publisher = "Frontiers Media S. A.",

}

Would screening for lung cancer benefit 75- to 84-year-old residents of the United States? / Varlotto, John M.; DeCamp, Malcolm M.; Flickinger, John C.; Lake, Jessica; Recht, Abram; Belani, Chandra P.; Reed, Michael F.; Toth, Jennifer W.; Mackley, Heath B.; Sciamanna, Christopher N.; Lipton, Alan; Ali, Suhail M.; Mahraj, Richkesvar P.M.; Gilbert, Christopher R.; Yao, Nengliang.

In: Frontiers in Oncology, Vol. 4 MAR, Article 37, 01.01.2014.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Would screening for lung cancer benefit 75- to 84-year-old residents of the United States?

AU - Varlotto, John M.

AU - DeCamp, Malcolm M.

AU - Flickinger, John C.

AU - Lake, Jessica

AU - Recht, Abram

AU - Belani, Chandra P.

AU - Reed, Michael F.

AU - Toth, Jennifer W.

AU - Mackley, Heath B.

AU - Sciamanna, Christopher N.

AU - Lipton, Alan

AU - Ali, Suhail M.

AU - Mahraj, Richkesvar P.M.

AU - Gilbert, Christopher R.

AU - Yao, Nengliang

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Background: The National Lung Screening Trial demonstrated that screening for lung cancer improved overall survival (OS) and reduced lung cancer mortality in the 55- to 74-year-old age group by increasing the proportion of cancers detected at an early stage. Because of the increasing life expectancy of the American population, we investigated whether screening for lung cancer might benefit men and women aged 75-84 years. Materials/Methods: Rates of non-small cell lung cancer (NSCLC) from 2000 to 2009 were calculated in both younger and older age groups using the surveillance epidemiology and end reporting database. OS and lung cancer-specific survival (LCSS) in patients with Stage I NSCLC diagnosed from 2004 to 2009 were analyzed to determine the effects of age and treatment. Results: The per capita incidence of NSCLC decreased in the 55-74 cohort, but increased in the 75-84 cohort over the study period. Crude lung cancer death rates in the two age groups who had no specific treatment were 39.5 and 44.9%, respectively. These rates fell in both age groups when increasingly aggressive treatment was used. Rates of OS and LCSS improved significantly with increasingly aggressive treatment in the 75-84 age group. The survival benefits of increasingly aggressive treatment in 75- to 84-year-old females did not differ from their counterparts in the younger cohort. Conclusion: Screening for lung cancer might be of benefit to individuals at increased risk of lung cancer in the 75-84 age group. The survival benefits of aggressive therapy are similar in females between 55-74 and 75-84 years old.

AB - Background: The National Lung Screening Trial demonstrated that screening for lung cancer improved overall survival (OS) and reduced lung cancer mortality in the 55- to 74-year-old age group by increasing the proportion of cancers detected at an early stage. Because of the increasing life expectancy of the American population, we investigated whether screening for lung cancer might benefit men and women aged 75-84 years. Materials/Methods: Rates of non-small cell lung cancer (NSCLC) from 2000 to 2009 were calculated in both younger and older age groups using the surveillance epidemiology and end reporting database. OS and lung cancer-specific survival (LCSS) in patients with Stage I NSCLC diagnosed from 2004 to 2009 were analyzed to determine the effects of age and treatment. Results: The per capita incidence of NSCLC decreased in the 55-74 cohort, but increased in the 75-84 cohort over the study period. Crude lung cancer death rates in the two age groups who had no specific treatment were 39.5 and 44.9%, respectively. These rates fell in both age groups when increasingly aggressive treatment was used. Rates of OS and LCSS improved significantly with increasingly aggressive treatment in the 75-84 age group. The survival benefits of increasingly aggressive treatment in 75- to 84-year-old females did not differ from their counterparts in the younger cohort. Conclusion: Screening for lung cancer might be of benefit to individuals at increased risk of lung cancer in the 75-84 age group. The survival benefits of aggressive therapy are similar in females between 55-74 and 75-84 years old.

UR - http://www.scopus.com/inward/record.url?scp=84900992973&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84900992973&partnerID=8YFLogxK

U2 - 10.3389/fonc.2014.00037

DO - 10.3389/fonc.2014.00037

M3 - Article

C2 - 24639950

AN - SCOPUS:84900992973

VL - 4 MAR

JO - Frontiers in Oncology

JF - Frontiers in Oncology

SN - 2234-943X

M1 - Article 37

ER -